Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacotherapy and clinical trial findings without systematic methodology
PubMed 20856911 · doi:10.2147/ndt.s5190
What was done
This narrative review summarizes the pharmacological rationale, clinical efficacy, and therapeutic role of combined carbidopa/levodopa/entacapone (Stalevo) in Parkinson disease, including outcomes from the STRIDE-PD trial and effects on homocysteine metabolism.
What was found
Levodopa induces motor complications in up to 80% of patients over time. Adding the COMT inhibitor entacapone increases levodopa brain availability and extends on-time in fluctuating patients. The single-tablet formulation (carbidopa/levodopa/entacapone) provides clinical improvements similar to separate tablets with improved quality of life. However, the STRIDE-PD study failed to demonstrate that initial treatment with triple therapy delays the onset of dyskinesias compared to conventional levodopa/carbidopa. Studies evaluating entacapone effect on plasma homocysteine levels showed contrasting results. No specific quantitative values or effect sizes were reported in the abstract.
Why it matters
The review clarifies that while triple combination therapy improves symptomatic control and on-time in fluctuating Parkinson disease, it does not prevent or delay the emergence of dyskinesia when initiated early.
Limits
This is a non-systematic narrative review containing no original patient data, formal search strategy, or meta-analytic pooling. Specific effect sizes, statistical measures, and participant numbers are omitted from the abstract.
Cited by
- supports Carbidopa blocks peripheral metabolism of levodopa, preventing it from converting into dopamine before crossing into the brain.